Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review

被引:0
作者
Deborah M. Siegal
Daniel Freedman
Jack Ansell
机构
[1] University of Ottawa,Department of Medicine
[2] Ottawa Hospital Research Institute,undefined
[3] Covis Pharma Group,undefined
[4] Hofstra/Northwell School of Medicine,undefined
来源
Journal of Thrombosis and Thrombolysis | 2023年 / 55卷
关键词
Oral anticoagulant therapy; Perioperative management; Direct oral anticoagulants; Warfarin;
D O I
暂无
中图分类号
学科分类号
摘要
There are limited data about the frequency of urgent surgical emergencies among patients receiving oral anticoagulants (OACs). We conducted a systematic literature review of Medline and EMBASE for published English-language articles of adult patients receiving oral anticoagulant treatment (vitamin K antagonists, apixaban, dabigatran, edoxaban, rivaroxaban) that reported on patients experiencing unplanned emergent or urgent surgery/procedure or trauma. Randomized trials, observational studies, and case series (50–100 cases) were included. The primary outcome was the frequency of unplanned urgent surgery or invasive procedures among OAC-treated patients with a focus on those not precipitated by the presence of major bleeding. The protocol was not registered. Funding was provided by Covis Pharmaceuticals. The search yielded 1367 potential studies of which 34 were included in the final review. One study reported the rate of urgent surgery/procedures among a large cohort of patients treated with dabigatran or warfarin for atrial fibrillation (~ 1% per year). Another study reported the rate of bleeding or urgent surgery among OAC-treated patients experiencing a fracture or trauma (0.489% per patient-year). The remaining 32 studies were cohorts of OAC-treated patients who received reversal or hemostatic therapies for major bleeding or urgent surgery. A median of 28.8% of these patients underwent surgery or invasive procedure. Urgent surgery appears to be a common, yet understudied complication during OAC treatment potentially associated with high rates of adverse outcomes. With increased eligibility for OACs, future studies evaluating the management and outcomes in this setting are needed.
引用
收藏
页码:197 / 202
页数:5
相关论文
共 283 条
  • [1] Kirchhof P(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-2962
  • [2] Benussi S(2019)Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant JAMA Intern Med 179 1469-1478
  • [3] Kotecha D(2022)Perioperative manage antithrombotic therapy Chest 162 E207-E243
  • [4] Douketis JD(2017)Association of atrial fibrillation and oral anticoagulant use with perioperative outcomes after major noncardiac surgery J Am Heart Assoc 139 77-81
  • [5] Spyropoulos A(2016)Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial Thromb Res 126 343-348
  • [6] Duncan J(2012)Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial Circulation 62 1006-1012
  • [7] Douketis JD(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 9 189-99
  • [8] Spyropoulos AC(2020)Incidence rates of bleeding and emergency surgery due to trauma or fracture among Japanese patients with non-valvular atrial fibrillation receiving oral anticoagulation therapy Cardiol Ther 9 167-188
  • [9] Murad MH(2020)Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese post-marketing surveillance study Cardiol Ther 120 27-35
  • [10] Tafur AJ(2020)Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program Thromb Haemost 49 59-65